Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management
Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Two-thirds of ASCVD patients in the US do not reach LDL-c <70 mg/dL after 2 years on LLT

Literature - June 30, 2021 - Cannon CP et al. - JAMA Cardiol. 2021

This prospective registry study in the US showed that only 17.1% of patients with ASCVD on LLT had their therapy intensified over the next 2 years. Only 31.7% of patients achieved LDL-c levels <70mg/dL at 2 years.

Real-world data of PCSK9i use in FH patients

News - June 2, 2021

EAS 2021 An interim-analysis of the HEYMANS study showed that the majority of FH (both HeFH and HoFH) patients have a history of CV events and comorbidities. Initiation of evolocumab in these patients resulted in reduced LDL-c levels, maintained throughout the study.

Safety of PCSK9 siRNA demonstrated in pooled data analysis

News - June 1, 2021

EAS 2021 A pooled data analysis of ORION-9, 10 and 11 showed no changes in hematological and immunological biomarkers in patients with ASCVD or risk equivalent treated with inclisiran over a treatment period of 540 days.

LDL-c goal attainment in high risk patients

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This e-learning consists of three expert discussions in which the current situation on LDL-c guidelines implementation, barriers of LDL-c goal attainment and solutions to improve the proportion of patients achieving their target goals are discussed.

Genetic testing for autosomal dominant hypercholesterolemia in Norwegian patients and relatives

Literature - Apr. 20, 2021 - Leren TP and Bogsrud MP. - Atherosclerosis. 2021

Heterozygous LDLR gene mutations were most prevalent when screening for autosomal dominant hypercholesterolemia in hypercholesterolemia patients and relatives from Norway.

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Literature - Apr. 20, 2021 - Wright RS et al. - J Am Coll Cardiol. 2021

This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.

Registry data of PCSK9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these.

Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.

FDA approves PCSK9 inhibitor for patients with HoFH

News - Apr. 6, 2021

The PCSK9 inhibitor alirocumab has been approved by the US Food and Drug Administration (FDA) as an adjunct to other LDL-c lowering therapies for the treatment of adult patients with homozygous familial hypercholesterolemia.

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD
Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and Kastelein talk about this topic in depth and exchange views.

Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.

Elevated MI risk in patients with HeFH with gene variants in both LDLR and PCSK9

Literature - Mar. 16, 2021 - Doi T, et al. - J Am Heart Assoc. 2021

Patients with LDLR and PCSK9 gene variants had higher levels of LDL-c and more frequent occurrence of nonfatal MI than those with single LDLR variants. This was especially observed in men.

PCSK9